You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 18, 2024

GLUCOVANCE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Glucovance, and when can generic versions of Glucovance launch?

Glucovance is a drug marketed by Bristol Myers Squibb and is included in one NDA.

The generic ingredient in GLUCOVANCE is glyburide; metformin hydrochloride. There are twenty drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the glyburide; metformin hydrochloride profile page.

Summary for GLUCOVANCE
Drug patent expirations by year for GLUCOVANCE
Drug Prices for GLUCOVANCE

See drug prices for GLUCOVANCE

Recent Clinical Trials for GLUCOVANCE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Texas Tech University Health Sciences Center, El PasoEarly Phase 1
Brigham and Women's HospitalPhase 4
Ortho Biotech Products, L.P.Phase 4

See all GLUCOVANCE clinical trials

US Patents and Regulatory Information for GLUCOVANCE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb GLUCOVANCE glyburide; metformin hydrochloride TABLET;ORAL 021178-001 Jul 31, 2000 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Bristol Myers Squibb GLUCOVANCE glyburide; metformin hydrochloride TABLET;ORAL 021178-002 Jul 31, 2000 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Bristol Myers Squibb GLUCOVANCE glyburide; metformin hydrochloride TABLET;ORAL 021178-003 Jul 31, 2000 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for GLUCOVANCE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb GLUCOVANCE glyburide; metformin hydrochloride TABLET;ORAL 021178-001 Jul 31, 2000 ⤷  Try a Trial ⤷  Try a Trial
Bristol Myers Squibb GLUCOVANCE glyburide; metformin hydrochloride TABLET;ORAL 021178-002 Jul 31, 2000 ⤷  Try a Trial ⤷  Try a Trial
Bristol Myers Squibb GLUCOVANCE glyburide; metformin hydrochloride TABLET;ORAL 021178-003 Jul 31, 2000 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for GLUCOVANCE

See the table below for patents covering GLUCOVANCE around the world.

Country Patent Number Title Estimated Expiration
Algeria 2846 Forme posologique à usage oral comprenant une combinaison de metformine et de glibenclamide. ⤷  Try a Trial
China 1146427 ⤷  Try a Trial
African Intellectual Property Organization (OAPI) 11400 Solid oral dosage form comprising a combination ofmetformin and glibenclamide. ⤷  Try a Trial
China 1486698 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.